Comprehensive Healthcare Solutions for Every Need

Stem Cell Transplants

The Bahrain Oncology Center announced its success in approving the Casgevy treatment, a new gene therapy used to treat blood disorders known as beta thalassemia and sickle cell disease in patients aged 12 and older. This is the first treatment approved by the U.S. Food and Drug Administration (FDA) that utilizes the advanced CRISPR/Cas9 gene-editing technology, marking a new achievement in the history of the Kingdom of Bahrain.

This treatment involves editing the patient’s stem cells using the CRISPR/Cas9 technique to correct the genetic defects causing the disease, significantly improving the patients' health condition.

The project was launched with the support of His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince, Deputy Supreme Commander, and Prime Minister. The Bahrain Oncology Center has received accreditation from Vertex to provide this advanced treatment for patients with sickle cell disease and thalassemia.

With this achievement, the Kingdom of Bahrain has positioned itself among the first countries globally to provide the CASGEVY (Exa-cel) treatment for sickle cell disease and thalassemia, demonstrating the kingdom's dedication to delivering cutting-edge therapies and enhancing healthcare standards.